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Diabetic retinopathy (DR) is a microvascular complication of diabetes leading 
to vision loss. Hypoxic/hyperglycaemic microenvironment is responsible of outer 
blood retinal barrier integrity impairment and uncontrolled vascularization typical of 
this pathology. Activation the hypoxia-inducible factors (HIFs) conduce to aberrant 
expression of some target genes such as vascular endothelial growth factor (VEGF). 
Many studies have showed the protective role of a small peptide, known as NAP, in 
counteract retinal damage induced by different insults (Gozes et al., 2004). In particu-
lar, we have previously demonstrated that a single intraocular dose of this peptide is 
able to protect retina from hyperglycaemic insult (Scuderi et al., 2014). However, the 
involvement of NAP in the modulation of HIFs and their downstream target genes 
has not been identified yet. In this work, we have instigated its effect on HIFs /VEGF 
system both in vitro and in vivo models of DR. Results have demonstrated that NAP 
treatment prevents outer BRB breakdown comprising human retinal pigmented epi-
thelial cells (ARPE-19) grown in transwell supports and exposed to high glucose 
(HG) and low oxygen tension by adding desferoxamine mesylate salt (DFX). Peptide 
administration also reduced HIF1α /HIF2α, VEGF/VEGFRs and increased HIF3α 
expression in cells cultured in HG/DFX. Moreover, it reduced apoptotic cells rate by 
modulating BAX and Bcl2 expression, two genes involved in programmed death.
Furthermore, NAP intraocular administration in STZ-induced diabetic rat reduced 
retinal expression of HIF-1α, HIF-2α and VEGF by increasing HIF-3α levels. These 
data have been also confirmed by immunolocalization analysis detected through con-
focal microscopy showing the different distribution of these factors in retinal layers 
following hyperglycaemic insult. 
Our data suggest that this small peptide may be efficacious in counteract retinal 
damages during DR.
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